March 17 (Reuters) - Pfizer said on Tuesday its experimental combination reduced the risk of disease progression or death by ...

By Padmanabhan Ananthan March 9 (Reuters) - U.S. drugmaker Pfizer said on Monday its experimental drug for a chronic skin ...

Pfizer’s CDK4 inhibitor, atirmociclib, is already being investigated in a Phase III trial as a first-line therapy.

Pfizer (PFE) stock is in focus as Xtandi, marketed with Astellas (ALPMF), and cancer drug Talzenna succeed in a Phase 3 trial for prostate cancer. Read more here.

While sales of Talzenna, which Pfizer acquired in a $14 billion deal, have been “negligible” so far, the new results should ...

Pfizer (PFE) stock is in focus as a mid-stage trial for the company's investigational breast cancer therapy, atirmociclib succeeds. Read more here.

Pfizer has reached a turning point.

As noted, Merck and Pfizer are both large pharmaceutical companies. Making and selling drugs is complex, expensive, and competitive. There are massive research and development costs involved in ...

Pfizer Inc. Chief Executive Albert Bourla had long searched for an obesity drug to make up for dwindling sales of the pharma company’s aging blockbusters. Late Friday, after a dramatic bidding war, he ...

They aren't just "pandemic stocks." ...

Right now, Pfizer's dividend payout ratio is above 100%. That suggests the dividend comes with some risk, which is true.